# US 10,370,343 B2 · [6,6] Fused bicyclic HDAC8 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,370,343 B2
- Document ID: US10370343B2
- Status: Granted
- Kind: B2
- Application number: 16/003,861
- Filed: 2018-06-08
- Published: 2018-12-13
- Granted: 2019-08-06
- Earliest claimed: 2015-09-03
- Assignees: FORMA Therapeutics, Inc.
- Applicants: FORMA Therapeutics, Inc.
- Inventors: Xiaozhang Zheng; Pui Yee Ng; Jennifer R. Thomason; Mary-Margaret Zablocki; Bingsong Han; Nicholas Barczak; Cuixian Liu; Aleksandra Rudnitskaya; David R. Lancia, Jr.; Kenneth W. Bair
- Web page: https://patentgrep.com/patent/US10370343B2

## CPC

- C07D 265/36: condensed with one six-membered ring
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 265/34: condensed with carbocyclic rings
- C07D 279/14: condensed with carbocyclic rings or ring systems
- C07D 279/16: condensed with one six-membered ring
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2′, L, X, W, Y1, Y2, Y3, and Y4 are described herein.

## Claims

### Claim 1

A composition comprising a compound selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The composition of claim 2, further comprising the compound:
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

The composition of claim 4, further comprising the compound:
or a pharmaceutically acceptable salt thereof.

### Claim 6

A composition comprising a compound selected from:
or a pharmaceutically acceptable salt thereof,
wherein the compound is obtained by a process comprising a step of treating a compound:
with hydroxylamine and a first base to form a compound:
wherein R1 is selected from the group consisting of:

### Claim 7 (depends on 6)

The composition of claim 6, wherein the first base comprises a hydroxide ion.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the first base is NaOH.

### Claim 9 (depends on 6)

The composition of claim 6, wherein the process further comprises a step of treating a compound:
with R1—X′, wherein X′ is halogen, and a second base to form the compound:

### Claim 10 (depends on 9)

The composition of claim 9, wherein the second base is NaH, K2CO3, or Cs2CO3.

### Claim 11 (depends on 9)

The composition of claim 9, wherein X′ is Cl or Br.

### Claim 12 (depends on 6)

The composition of claim 6, wherein the composition comprises:
or a pharmaceutically acceptable salt thereof,
wherein the compound is obtained by a process, comprising the step of treating the compound:
with hydroxylamine and a first base to form the compound:

### Claim 13 (depends on 12)

The composition of claim 12, wherein the process further comprises the step of treating the compound:
with R1—X′, wherein X′ is halogen, and a second base to form the compound:

### Claim 14 (depends on 6)

The composition of claim 6, wherein the composition comprises:
or a pharmaceutically acceptable salt thereof,
wherein the compound is obtained by a process, comprising the step of treating the compound:
with hydroxylamine and a first base to form the compound:

### Claim 15 (depends on 14)

The composition of claim 14, wherein the process further comprises the step of treating the compound:
with R1—X′, wherein X′ is halogen, and a second base to form the compound:

### Claim 16

A composition comprising a first compound selected from:
and
a second compound:

### Claim 17 (depends on 16)

The composition of claim 16, wherein the first compound is:

### Claim 18 (depends on 16)

The composition of claim 16, wherein the first compound is: